Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.35 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PKLR | P30613 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24476314 | 0.89 | DPP4 (0.39) | DPP4DPP7S1PR1HDAC6SLC9A1 | |
| SCHEMBL19981291 | 0.86 | VSIR (0.42) | DPP4DPP7S1PR1VSIRCD274 | |
| SCHEMBL24218473 | 0.84 | S1PR1 (0.35) | DPP4DPP7S1PR1VSIRCD274 | |
| SCHEMBL19981159 | 0.81 | DPP4 (0.38) | DPP4DPP7S1PR1HDAC6SLC9A1 | |
| SCHEMBL19981143 | 0.78 | DPP4 (0.34) | DPP4DPP7S1PR1HDAC6SLC9A1 | |
| SCHEMBL19981308 | 0.77 | BMP1 (0.39) | DPP4DPP7VSIRCD274 | |
| SCHEMBL18078241 | 0.76 | VSIR (0.56) | VSIRCD274 | |
| SCHEMBL18078016 | 0.75 | DPP4 (0.45) | DPP4DPP7S1PR1SLC9A1CTSA | |
| SCHEMBL19867093 | 0.75 | CD274 (0.58) | DPP4DPP7S1PR1VSIRCD274 | |
| SCHEMBL18077936 | 0.75 | CD274 (0.58) | DPP4DPP7S1PR1VSIRCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168268-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2022-06-02 | — | — | US | disclosed |
| EP-3943083-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020192570-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | 上海再极医药科技有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2018051254-A1 | CYCLIC SUBSTITUTED-1,2,4-OXADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168268-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | PDCD1, PDCD1LG2, CD274 | DPP4 3242/4885DPP7 2490/4885S1PR1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.